Predictive Oncology Strengthens Offerings with GMP Lab and Addition of Leading Expert in Formulation Development
EAGAN, Minn., Sept. 19, 2022 (GLOBE NEWSWIRE) — Predictive Oncology (NASDAQ:POAI) today announced several key developments to further strengthen the company’s offerings for pharmaceutical and biotech customers.
Related news for (POAI)
- Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
- UPDATE – Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
- 24/7 Market News Snapshot 22 May, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)
- Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
- 24/7 Market News Snapshot 22 May, 2025 – Predictive Oncology Inc. Common Stock (NASDAQ:POAI)